In vitro testing of drug absorption for drug 'developability' assessment: Forming an interface between in vitro preclinical data and clinical outcome

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 1, 2004, Pages 75-85

  Sun, Duxin ^a   Yu, Lawrence X ^b   Hussain, Munir A ^c   Wall, Doris A ^c   Smith, Ronald L ^c   Amidon, Gordon L ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biopharmaceutics classification system; Fraction of drug absorbed; In vitro in vivo correlation; Maximum absorbable dose; Permeability; Prodrug

Indexed keywords

PRODRUG; DRUG;

CALCULATION; CELL STRAIN CACO 2; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; REVIEW; TOXICITY; TREATMENT OUTCOME; BIOLOGICAL MODEL; CHEMISTRY; DRUG DESIGN; INTESTINE ABSORPTION; METABOLISM; METHODOLOGY; PERMEABILITY; PHARMACOKINETICS; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRODRUGS; SOLUBILITY; TREATMENT OUTCOME;

EID: 2942585051     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Sun D, Lennemas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL: Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 19(10):1400-1416. A study suggesting that in vitro and in vivo permeabilities correlate better at pH 6.5 than at pH 7.4; the difference in permeability in vitro and in vivo for drugs absorbed through transporters is due to the different egression in Caco2 cells and human intestine.
2. Kwan KC: Oral bioavailability and first-pass effects. Drug Metab Dispos (1997) 25(12):1329-1336.
3. Lennemǎs H: Human intestinal permeability. J Pharm Sci (1998) 87(4):403-410. A review summarizing the different methods for measuring permeability; the correlation analysis of several compounds is also presented.
4. van de Waterbeemd H: The fundamental variables of the biopharmaceutics classification system (BCS): A commentary. Eur J Pharm Sci (1998) 7(1):1-3.
5. Lennemǎs H, Nylander S, Ungell AL: Jejunal permeability: A comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm Res (1997) 14(5):667-671.
6. Amidon GL, Sinko PJ, Reisher D: Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res (1988) 5(10):651-654.
7. Amidon GL, Lennemǎs H, Shah VP, Crison JR: A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12(3):413-420. The BCS, based on modeling and experimental measurements, is presented. This paper is the fundamental publication for FDA guidance of waiver of in vivo bioavailability and bioequivalence studies for Immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
8. Oh DM, Curl RL, Amidon GL: Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: A mathematical model. Pharm Res (1993) 10(2):264-270.
9. Yu LX, Upka E, Crison JR, Amidon GL: Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 19(3):359-376. This review describes new methods to calculate the fraction of drug absorbed based on permeability data when drug concentration in intestinal lumen is greater or less than the drug solubility.
10. Curatolo W: Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Science Tech Today (1998) 1(9):387-393. The prediction of MAD is introduced using in vivo absorption rate constant.
11. Dressman JB, Amidon GL, Reppas C, Shah VP: Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res (1998) 15(1):11-22.
12. 2 is established for drug intestinal absorption.
13. Fade V, Stavchansky S: Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci (1998) 87(12):1604-1607.
14. Chong S, Dando SA, Soucek KM, Morrison RA: In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res (1996) 13(1):120-123.
15. Yee S: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm Res (1997) 14(6):763-766.
16. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H: Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci (2000) 10(3):195-204.
17. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS: Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Hes (2002) 19(7):921-925.
18. Sun D, Landowski CP, Chu X, Wallsten R, Komorowski TE, Reisher D, Amidon GL: Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein. AAPS PharmSci (2001) 3(1):E2.